Skip to content

CHINA PHARMA HOLDINGS, INC.: 10-Q filed 2023-11-13

What CHINA PHARMA HOLDINGS, INC. reported in its quarterly report filed 2023-11-13 (fiscal Q3 2023): 47 published measures, 142 facts as tagged in accession 0001213900-23-086100.

This filing

Form
10-Q (quarterly report)
Filed
2023-11-13
Fiscal period
fiscal Q3 2023
Accession
0001213900-23-086100 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CHINA PHARMA HOLDINGS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-09-3015,352,357USD
At 2022-12-3117,784,143USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-09-309,241,475USD
At 2022-12-3113,494,145USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-09-306,110,882USD
At 2023-06-304,352,628USD
At 2023-03-314,669,344USD
At 2022-12-314,289,998USD
At 2022-09-302,834,929USD
At 2022-06-304,024,688USD
At 2022-03-315,340,040USD
At 2021-12-316,017,881USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-09-301,369,871USD
At 2022-12-312,029,971USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-777,600USD92
2023-01-01 to 2023-09-30-1,846,605USD273
2023-04-01 to 2023-06-30-593,029USD91
2023-01-01 to 2023-03-31-475,976USD90
2022-07-01 to 2022-09-30-790,773USD92
2022-01-01 to 2022-09-30-2,708,657USD273
2022-04-01 to 2022-06-30-888,394USD91
2022-01-01 to 2022-03-31-1,029,490USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-09-30-677,363USD273
2022-01-01 to 2022-09-30-994,139USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2023-07-01 to 2023-09-301,803,461USD92
2023-01-01 to 2023-09-304,861,613USD273
2022-07-01 to 2022-09-301,965,931USD92
2022-01-01 to 2022-09-305,183,092USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-09-3042,767USD273
2022-01-01 to 2022-09-30-1,097,944USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-09-30-6,990USD273
2022-01-01 to 2022-09-30-429,232USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-09-30-38,058,101USD
At 2022-12-31-36,211,496USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-07-01 to 2023-09-3013,216,345shares92
2023-01-01 to 2023-09-3010,422,589shares273
2022-07-01 to 2022-09-305,002,851shares92
2022-01-01 to 2022-09-304,863,818shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-0.06USD/shares92
2023-01-01 to 2023-09-30-0.18USD/shares273
2022-07-01 to 2022-09-30-0.16USD/shares92
2022-01-01 to 2022-09-30-0.56USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-0.06USD/shares92
2023-01-01 to 2023-09-30-0.18USD/shares273
2022-07-01 to 2022-09-30-0.16USD/shares92
2022-01-01 to 2022-09-30-0.56USD/shares273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-09-307,768,497USD
At 2022-12-319,973,065USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-713,542USD92
2023-01-01 to 2023-09-30-1,567,329USD273
2022-07-01 to 2022-09-30-688,654USD92
2022-01-01 to 2022-09-30-2,379,965USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-09-305,807,298USD
At 2022-12-315,964,546USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-07-01 to 2023-09-3066,240USD92
2023-01-01 to 2023-09-30283,348USD273
2022-07-01 to 2022-09-30103,976USD92
2022-01-01 to 2022-09-30338,444USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-09-307,057,806USD
At 2022-12-3112,739,447USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2023-09-301,642,357USD
At 2022-12-311,807,486USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2023-09-30368,227USD
At 2022-12-31421,531USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-07-01 to 2023-09-30480,352USD92
2023-01-01 to 2023-09-301,365,402USD273
2022-07-01 to 2022-09-30550,898USD92
2022-01-01 to 2022-09-301,843,367USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2023-09-303,767,014USD
At 2022-12-312,947,787USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-233,190USD92
2023-01-01 to 2023-09-30-201,927USD273
2022-07-01 to 2022-09-30-137,756USD92
2022-01-01 to 2022-09-30-536,598USD273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2023-07-01 to 2023-09-302,036,651USD92
2023-01-01 to 2023-09-305,063,540USD273
2022-07-01 to 2022-09-302,103,687USD92
2022-01-01 to 2022-09-305,719,690USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-07-01 to 2023-09-3045,773USD92
2023-01-01 to 2023-09-3092,528USD273
2022-07-01 to 2022-09-3088,747USD92
2022-01-01 to 2022-09-30157,859USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-09-3028,723,624shares
At 2022-12-317,490,896shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-09-301,369,871USD
At 2022-12-312,029,971USD
At 2022-09-302,086,298USD
At 2021-12-314,859,060USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-09-3032,738,108USD
At 2022-12-3128,853,520USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2023-09-3011,326,102USD
At 2022-12-3111,573,065USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-09-30134,205USD
At 2022-12-3139,046USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2023-09-30134,794USD
At 2022-12-3140,445USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2023-09-3037,121,826USD
At 2022-12-3138,323,430USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2023-09-3029,353,329USD
At 2022-12-3128,350,365USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2023-09-301,642,357USD
At 2022-12-311,807,486USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2023-09-30119,669USD
At 2022-12-31404,807USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2023-09-30172,110USD
At 2022-12-31520,295USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2023-09-30732,078USD
At 2022-12-31754,698USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-777,600USD92
2023-01-01 to 2023-09-30-1,846,605USD273
2022-07-01 to 2022-09-30-790,773USD92
2022-01-01 to 2022-09-30-2,708,657USD273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-777,606USD92
2023-01-01 to 2023-09-30-2,093,568USD273
2022-07-01 to 2022-09-30-1,389,759USD92
2022-01-01 to 2022-09-30-3,882,952USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-07-01 to 2023-09-30246,267USD92
2023-01-01 to 2023-09-30776,299USD273
2022-07-01 to 2022-09-30276,611USD92
2022-01-01 to 2022-09-301,063,835USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-07-01 to 2023-09-30630,579USD92
2023-01-01 to 2023-09-301,896,279USD273
2022-07-01 to 2022-09-30655,386USD92
2022-01-01 to 2022-09-302,033,194USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2023-01-01 to 2023-09-302,057,818USD273
2022-01-01 to 2022-09-302,061,108USD273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2023-07-01 to 2023-09-3052,514USD92
2023-01-01 to 2023-09-30161,538USD273
2022-07-01 to 2022-09-308,951USD92
2022-01-01 to 2022-09-3027,914USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-64,058USD92
2023-01-01 to 2023-09-30-279,276USD273
2022-07-01 to 2022-09-30-102,119USD92
2022-01-01 to 2022-09-30-328,692USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-01-01 to 2023-09-30192,548USD273
2022-01-01 to 2022-09-30113,392USD273

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2023-07-01 to 2023-09-3020,142USD92
2023-01-01 to 2023-09-3059,667USD273
2022-07-01 to 2022-09-3020,060USD92
2022-01-01 to 2022-09-3042,554USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-09-30275,717USD273
2022-01-01 to 2022-09-30-496,202USD273

Inspect the source

Entity
CHINA PHARMA HOLDINGS, INC. / CIK 0001106644
Captured
2026-09-20T05:23:28.377Z
SEC response SHA-256
ad45dffd15d0f5a098ab8b6912816a8b1b845b1d791781ea412833d3178873c0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001106644.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))